PROCEPT BioRobotics Corp Cash Flow Statement
PRCT / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
PROCEPT BioRobotics Corp used $49M in operating cash flow and negative free cash flow of $58M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$95.6M | -$91.4M | -$105.9M | -$87.2M | -$59.9M | -$53.0M |
| Depreciation & Amortization | $6.4M | $5.2M | $3.8M | $2.8M | $3.3M | $2.9M |
| Operating Cash Flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M | -$57.3M | -$48.3M |
| Capital Expenditures | $9.4M | $4.4M | $25.2M | $2.7M | $592.0K | $233.0K |
| Free Cash Flow | -$58.3M | -$103.6M | -$133.2M | -$83.0M | -$57.9M | -$48.6M |
| FCF Margin | -18.9% | -46.2% | - | - | - | - |